Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

GSPT1 degrader

DRUG CLASS:

GSPT1 degrader

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MYCL expression	Non Small Cell Lung Cancer	MYCL expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials MRT-2359 Sensitive : B	MRT-2359 Sensitive: B - Late Trials MRT-2359 Sensitive : B
MYCN expression	Non Small Cell Lung Cancer	MYCN expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials MRT-2359 Sensitive : B	MRT-2359 Sensitive: B - Late Trials MRT-2359 Sensitive : B
GSPT1 deletion	Acute Lymphocytic Leukemia	GSPT1 deletion	Acute Lymphocytic Leukemia	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D
MYC overexpression	Non Small Cell Lung Cancer	MYC overexpression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: D – Preclinical MRT-2359 Sensitive : D	MRT-2359 Sensitive: D – Preclinical MRT-2359 Sensitive : D
GSPT1 deletion	Breast Cancer	GSPT1 deletion	Breast Cancer	ORM-5029 Sensitive: D – Preclinical ORM-5029 Sensitive : D	ORM-5029 Sensitive: D – Preclinical ORM-5029 Sensitive : D
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	ORM-5029 Sensitive: D – Preclinical ORM-5029 Sensitive : D	ORM-5029 Sensitive: D – Preclinical ORM-5029 Sensitive : D